CHMP backs Actelion's Opsumit, Lundbeck's Brintellix

EMA's CHMP on Friday backed approval of Opsumit macitentan from Actelion Ltd. (SIX:ATLN) to treat pulmonary arterial hypertension (PAH) and Brintellix vortioxetine from H. Lundbeck A/S (CSE:LUN) to treat major depressive disorder (MDD). FDA approved both drugs earlier this month. Opsumit is a tissue-targeting endothelin receptor antagonist, and Brintellix is a serotonin modulator and stimulator. Lundbeck is partnered for Brintellix in the U.S. and Japan with Takeda Pharmaceutical Co. Ltd. (Tokyo:4502). ...